CY1108217T1 - Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης - Google Patents

Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης

Info

Publication number
CY1108217T1
CY1108217T1 CY20081100780T CY081100780T CY1108217T1 CY 1108217 T1 CY1108217 T1 CY 1108217T1 CY 20081100780 T CY20081100780 T CY 20081100780T CY 081100780 T CY081100780 T CY 081100780T CY 1108217 T1 CY1108217 T1 CY 1108217T1
Authority
CY
Cyprus
Prior art keywords
depression
buprenorfine
administration
buprenorphine
department treatment
Prior art date
Application number
CY20081100780T
Other languages
Greek (el)
English (en)
Inventor
Robert F Kaiko
Ramiro Sanchez
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1108217T1 publication Critical patent/CY1108217T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CY20081100780T 2002-03-20 2008-07-28 Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης CY1108217T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
EP03721427A EP1485051B1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (1)

Publication Number Publication Date
CY1108217T1 true CY1108217T1 (el) 2014-02-12

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100780T CY1108217T1 (el) 2002-03-20 2008-07-28 Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης

Country Status (12)

Country Link
US (1) US20030181475A1 (https=)
EP (1) EP1485051B1 (https=)
JP (1) JP2005528359A (https=)
AT (1) ATE394097T1 (https=)
AU (1) AU2003224742A1 (https=)
CY (1) CY1108217T1 (https=)
DE (1) DE60320770D1 (https=)
DK (1) DK1485051T3 (https=)
ES (1) ES2305457T3 (https=)
PT (1) PT1485051E (https=)
SI (1) SI1485051T1 (https=)
WO (1) WO2003079945A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297073A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
SI1646328T1 (sl) 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
AU2012351805B2 (en) * 2011-12-15 2016-04-21 Alkermes Pharma Ireland Limited Samidorphan (ALKS 33) in combination with opioid agonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
LT3153171T (lt) * 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
EP0484543B1 (en) * 1990-04-24 1995-12-13 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US6165499A (en) * 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
AU2003224742A1 (en) 2003-10-08
US20030181475A1 (en) 2003-09-25
SI1485051T1 (sl) 2008-10-31
PT1485051E (pt) 2008-07-09
JP2005528359A (ja) 2005-09-22
DK1485051T3 (da) 2008-09-08
EP1485051B1 (en) 2008-05-07
EP1485051A4 (en) 2006-05-24
EP1485051A1 (en) 2004-12-15
ES2305457T3 (es) 2008-11-01
DE60320770D1 (de) 2008-06-19
ATE394097T1 (de) 2008-05-15
WO2003079945A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
SE9902597D0 (sv) New use
IS8186A (is) Meðferð fyrir uppskurð á verkjum eftir uppskurð
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
EP1795189A3 (en) Method of administering buprenorphine to treat depression
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
CY1113524T1 (el) Μεθοδοι χαμηλης δοσης για τη θεραπεια διαταραχων στις οποιες η δραστικοτητα του tnfα ειναι επιβλαβης
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EA200000514A1 (ru) Способ лечения эректильной дисфункции